<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2019-05-20" updated="2019-11-02">
  <drugbank-id primary="true">DB15321</drugbank-id>
  <name>Tefinostat</name>
  <description>Tefinostat is under investigation in clinical trial NCT02759601 (Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)).</description>
  <cas-number>914382-60-8</cas-number>
  <unii>ZAU91150SB</unii>
  <average-mass>495.62</average-mass>
  <monoisotopic-mass>495.273321303</monoisotopic-mass>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amides</category>
      <mesh-id>D000577</mesh-id>
    </category>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Aniline Compounds</category>
      <mesh-id>D000814</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Histone Deacetylase Inhibitors</category>
      <mesh-id>D056572</mesh-id>
    </category>
    <category>
      <category>Hydroxy Acids</category>
      <mesh-id>D006880</mesh-id>
    </category>
    <category>
      <category>Hydroxylamines</category>
      <mesh-id>D006898</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tefinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tefinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tefinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tefinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Tefinostat is combined with Vorinostat.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.91</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.20e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.48</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>cyclopentyl (2S)-2-[({4-[7-(hydroxycarbamoyl)heptanamido]phenyl}methyl)amino]-2-phenylacetate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2R)-14-fluoro-2-methyl-6,9,10,19-tetraazapentacyclo[14.2.1.0^{2,6}.0^{8,18}.0^{12,17}]nonadeca-1(18),8,12(17),13,15-pentaen-11-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>495.62</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>495.273321303</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>ONC(=O)CCCCCCC(=O)NC1=CC=C(CN[C@H](C(=O)OC2CCCC2)C2=CC=CC=C2)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C28H37N3O5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C28H37N3O5/c32-25(14-6-1-2-7-15-26(33)31-35)30-23-18-16-21(17-19-23)20-29-27(22-10-4-3-5-11-22)28(34)36-24-12-8-9-13-24/h3-5,10-11,16-19,24,27,29,35H,1-2,6-9,12-15,20H2,(H,30,32)(H,31,33)/t27-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>GLNWREBYRLDPQP-MHZLTWQESA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>116.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>138.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>55.59</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>15</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>8.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>4.71</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>13083627</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>